Shuchi S. Pandya

5.9k total citations · 3 hit papers
69 papers, 2.1k citations indexed

About

Shuchi S. Pandya is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Shuchi S. Pandya has authored 69 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 22 papers in Genetics. Recurrent topics in Shuchi S. Pandya's work include Glioma Diagnosis and Treatment (15 papers), Pancreatic and Hepatic Oncology Research (15 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers). Shuchi S. Pandya is often cited by papers focused on Glioma Diagnosis and Treatment (15 papers), Pancreatic and Hepatic Oncology Research (15 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers). Shuchi S. Pandya collaborates with scholars based in United States, France and Spain. Shuchi S. Pandya's co-authors include Weiwei Tan, Keith D. Wilner, Zhongzhou Shen, Susumu Kobayashi, Wee-Lee Yeo, Daniel B. Costa, Geoffrey I. Shapiro, James M. Cleary, Eunice L. Kwak and Camelia Gliser and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Shuchi S. Pandya

64 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

2011 474 citations Shuchi S. Pandya et al. Journal of Clinical Oncology profile →
Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

2022 295 citations Shuchi S. Pandya, Stéphane de Botton et al. profile →
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

2023 111 citations Ingo K. Mellinghoff, Min Lu et al. Nature Medicine profile →

Peers

Countries citing papers authored by Shuchi S. Pandya

Since Specialization

Citations

This map shows the geographic impact of Shuchi S. Pandya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuchi S. Pandya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuchi S. Pandya more than expected).

Fields of papers citing papers by Shuchi S. Pandya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuchi S. Pandya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuchi S. Pandya. The network helps show where Shuchi S. Pandya may publish in the future.

Co-authorship network of co-authors of Shuchi S. Pandya

This figure shows the co-authorship network connecting the top 25 collaborators of Shuchi S. Pandya. A scholar is included among the top collaborators of Shuchi S. Pandya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuchi S. Pandya. Shuchi S. Pandya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Post-Operative Ludwig's Angina in an 11-Year-Old: An Atypical Case of Unknown Aetiology 2025 ·International Journal of Oral and Maxillofacial Surgery ·(unknown), Shuchi S. Pandya, (unknown)	0
2	10311- ACT-19 A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS 2024 ·Neuro-Oncology Advances ·Martin J. van den Bent, Ingo K. Mellinghoff, Mehdi Touat, Deborah T. Blumenthal, Katherine B. Peters, Benjamin M. Ellingson, Joe Mendez, Shlomit Yust‐Katz, Warren Mason, Andreas F. Hottinger, Yoshiki Arakawa, Juan Manuel Sepúlveda-Sánchez, Wolfgang Wick, Adriana E. Tron, (unknown), Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy	2
3	Circulating biomarkers in high-grade gliomas: current insights and future perspectives 2024 ·Journal of Neuro-Oncology ·(unknown), Ahmed Habib, (unknown), (unknown), (unknown), (unknown), Anthony Tang, Shuchi S. Pandya, Avichal Mehra, Hansen Deng, (unknown), (unknown), (unknown), Pascal O. Zinn	2
4	Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study 2024 ·Cancer Chemotherapy and Pharmacology ·Bin Fan, Ghassan K. Abou‐Alfa, Andrew X. Zhu, Shuchi S. Pandya, Hongxia Jia, Feng Yin, Camelia Gliser, Zhaowei Hua, Mohammad Sharif Hossain, Hua Yang	4
5	An Unanticipated Case of C1Q Nephropathy Diagnosed after Re-biopsy 2024 ·Journal of the American Society of Nephrology ·Shuchi S. Pandya, (unknown), (unknown)	0
6	KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION 2023 ·Neuro-Oncology ·Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Jose Carlos Méndez, Liam Welsh, Warren Mason, Andreas F. Hottinger, Juan Manuel Sepúlveda-Sánchez, Wolfgang Wick, Riccardo Soffietti, Steve Schoenfeld, Dongdong Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy	0
7	Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study 2023 ·American Journal of Hematology ·Courtney D. DiNardo, Stéphane de Botton, Daniel A. Pollyea, Richard M. Stone, Jessica K. Altman, Amir T. Fathi, Tharin Limsakun, (unknown), Sung Choe, Mohammad Sharif Hossain, Adriana E. Tron, (unknown), Stephanie M. Kapsalis, Shuchi S. Pandya, Eytan M. Stein	5
8	498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma 2023 ·Annals of Oncology ·Deborah T. Blumenthal, Ingo K. Mellinghoff, Martin J. van den Bent, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Joe Mendez, Liam Welsh, Warren Mason, Andreas F. Hottinger, Juan Manuel Sepúlveda-Sánchez, Wolfgang Wick, Riccardo Soffietti, (unknown), Dongdong Zhao, Shuchi S. Pandya, Linda S. Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy	2
9	Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial breakdown → 2023 ·Nature Medicine ·Ingo K. Mellinghoff, Min Lu, Patrick Y. Wen, Jennie Taylor, Elizabeth A. Maher, Isabel Arrillaga‐Romany, Katherine B. Peters, Benjamin M. Ellingson, Marc K. Rosenblum, Saewon Chun, Kha Le, Anna M. Tassinari, Sung Choe, Youssef Toubouti, Steven Schoenfeld, Shuchi S. Pandya, Islam Hassan, Lori Steelman, Jennifer Clarke, Timothy F. Cloughesy	111
10	Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study 2021 ·Blood ·Wendy Stock, Jae H. Park, Ashkan Emadi, Maher Abdul‐Hay, Ryan D. Cassaday, Vinod Pullarkat, Jonathan Webster, Shuchi S. Pandya, (unknown), (unknown), (unknown), (unknown), Daniel J. DeAngelo	1
11	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors 2019 ·Investigational New Drugs ·Bin Fan, Ingo K. Mellinghoff, Patrick Y. Wen, Maeve A. Lowery, Lipika Goyal, William D. Tap, Shuchi S. Pandya, (unknown), Liewen Jiang, Guowen Liu, (unknown), Camelia Gliser, (unknown), Sam Agresta, Hua Yang, David L. Dai	71
12	INFECTIOUS RISKS AND COMPLICATIONS IN ADULT LEUKEMIC PATIENTS RECEIVING BLINATUMOMAB 2018 ·Mediterranean Journal of Hematology and Infectious Diseases ·Wonhee So, Shuchi S. Pandya, (unknown), (unknown), John N. Greene	5
13	Two cases of disseminated infection following live organism anti-cancer vaccine administration in cancer patients 2018 ·International Journal of Infectious Diseases ·(unknown), Dae Hyun Lee, (unknown), Shuchi S. Pandya, Sadaf Aslam, (unknown), John N. Greene	12
14	Atypical manifestation of herpes esophagitis in an immunocompetent patient: Case report and literature review 2017 ·(unknown), Sajiv Sethi, Shuchi S. Pandya, Sowmya Nanjappa, John N. Greene	1
15	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma 2016 ·Clinical Cancer Research ·Martin H. Voss, Rupal S. Bhatt, Elizabeth R. Plimack, Brian I. Rini, Robert Alter, J. Thaddeus Beck, Dawn Wilson, Xiaosha Zhang, (unknown), Chad Glasser, Kenneth M. Attie, Matthew L. Sherman, Shuchi S. Pandya, Michael B. Atkins	21
16	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors 2015 ·Investigational New Drugs ·Suzanne F. Jones, Lillian L. Siu, Johanna C. Bendell, James M. Cleary, Albiruni R. Abdul Razak, Jeffrey R. Infante, Shuchi S. Pandya, Philippe L. Bédard, Kristen J. Pierce, Brett E. Houk, W. Gregory Roberts, S. Martin Shreeve, Geoffrey I. Shapiro	125
17	DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1. 2015 ·Journal of Clinical Oncology ·Martin H. Voss, Elizabeth R. Plimack, Brian I. Rini, Michael B. Atkins, Robert Alter, Rupal S. Bhatt, J. Thaddeus Beck, (unknown), Dawn Wilson, Xiaosha Zhang, Matthew L. Sherman, Shuchi S. Pandya	2
18	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Geoffrey I. Shapiro, Jordi Rodón, Cynthia Bedell, Eunice L. Kwak, José Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, Alexander Laird, Linh T. Nguyen, Yi Xu, Coumaran Égile, Gerald M. Edelman	123
19	Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer 2011 ·British Journal of Urology ·Shuchi S. Pandya, James W. Mier, David F. McDermott, Daniel C. Cho	5
20	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors 2010 ·Clinical Cancer Research ·Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells A. Messersmith, Geoffrey I. Shapiro	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact